Search the Newsreel

Veracyte, Inc. Revenue Breakdown – TRADEGATE:12V

Veracyte, Inc. generated €440.31 million in revenue last year, primarily from its Diagnostic Tests and Biopharmaceutical Services segment. The United States was the leading contributor to this revenue, accounting for €422.81 million. This shows an increase in both total revenue and U.S. contributions compared …

Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Veracyte Inc (VCYT), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests VCYT is suitable for range-bound swing trading, with indicators showing mixed signals …

Veracyte to present at two major healthcare investor conferences in August and September 2026

Veracyte, a cancer diagnostics company, announced its participation in two key healthcare investor conferences: the Canaccord Genuity Growth Conference in August and the Morgan Stanley Global Healthcare Conference in September 2026. The company will conduct fireside chats at both events to discuss its diagnostic …

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences: Canaccord Genuity 46th Annual Growth Conference – Boston, MA Fireside chat on Tuesday, …

Veracyte to offer live audio webcasts for two investor chats

Veracyte (Nasdaq: VCYT) announced its participation in two upcoming investor conferences: the Canaccord Genuity 46th Annual Growth Conference on August 11, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company will host live audio webcasts and 90-day replays of …

Veracyte Inc (VCYT) Institutional Confidence

Veracyte Inc's institutional shareholding score is 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion increased by 6.15% quarter-over-quarter to 120.44%. Catherine Wood is the largest institutional shareholder, holding 2.21 million shares, representing 3.83% of outstanding shares.

Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Veracyte Inc (VCYT)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock performance data for VCYT, including its market cap and …

VCYT|Veracyte Inc|Price:56.610|Chg%:-1.270

This article provides a detailed financial overview of Veracyte Inc. (VCYT), including its stock performance, market capitalization, P/E ratio, and upcoming earnings information. It presents comprehensive quarterly and annual financial data, such as EPS, revenue, net profit, margins, and balance sheet items, allowing investors …

Veracyte Inc (VCYT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Veracyte Inc (VCYT), indicating its current score is 7.18 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of 49.88, noting its relation to recent highs and lows. While the P/E ratio is …

ETFs Investing in Veracyte, Inc. Stocks

This article lists various ETFs that hold Veracyte, Inc. (12V on the Frankfurt Stock Exchange) stocks. It provides detailed financial information for each ETF, including market value, weight of Veracyte stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, and NAV total …

Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline

The market expects Veracyte (VCYT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence …

Brittan McClanahan Starts a New Leadership Role at Veracyte

Brittan McClanahan has transitioned from BostonGene to Veracyte, Inc., where she will serve as General Manager of Biopharma Partnerships. At Veracyte, she is tasked with building the biopharma partnerships function from the ground up, a challenge she embraces after her previous experience designing enterprise …

Veracyte, Inc. (VCYT) Stock Analysis: Impressive Revenue Growth Amidst Strong Buy Ratings

Piper Sandler initiates Veracyte stock with overweight rating

Piper Sandler has initiated coverage on Veracyte (NASDAQ:VCYT) with an overweight rating and a price target of $66.00, citing the company's cash-generative diagnostics lab anchored by its Afirma and Decipher Prostate genomic classifiers. These products are expected to drive significant growth for years, with …

All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings

Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are

Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?